Home > Research > Publications & Outputs > Immunomodulatory treatment for amyotrophic late...

Research

Associated organisational unit

Electronic data

  • Malhotra_et_al-2022-Cochrane_Database_of_Systematic_Reviews

    Rights statement: This is the version of record of the following protocolMalhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA, Chhetri SK, Mulvaney CA, Villanueva G. Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD013945. DOI: 10.1002/14651858.CD013945. Accessed 12 September 2022 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013945/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

    Final published version, 165 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol)

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol). / Malhotra, H.S.; Singh, B.P.; Kumar, N. et al.
In: Cochrane Database of Systematic Reviews, Vol. 2022, No. 6, CD013945, 24.06.2022.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Malhotra, HS, Singh, BP, Kumar, N, Garg, RK, Kirubakaran, R, Emsley, HCA, Chhetri, SK, Mulvaney, CA & Villanueva, G 2022, 'Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol)', Cochrane Database of Systematic Reviews, vol. 2022, no. 6, CD013945. https://doi.org/10.1002/14651858.CD013945

APA

Malhotra, H. S., Singh, B. P., Kumar, N., Garg, R. K., Kirubakaran, R., Emsley, H. C. A., Chhetri, S. K., Mulvaney, C. A., & Villanueva, G. (2022). Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol). Cochrane Database of Systematic Reviews, 2022(6), Article CD013945. https://doi.org/10.1002/14651858.CD013945

Vancouver

Malhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA et al. Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol). Cochrane Database of Systematic Reviews. 2022 Jun 24;2022(6):CD013945. doi: 10.1002/14651858.CD013945

Author

Malhotra, H.S. ; Singh, B.P. ; Kumar, N. et al. / Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol). In: Cochrane Database of Systematic Reviews. 2022 ; Vol. 2022, No. 6.

Bibtex

@article{7e956416064f4bd4a2c0b1a71e97c2a3,
title = "Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol)",
abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the efficacy and harms or adverse events of immunomodulatory therapies in people with ALS compared with a placebo, no additional treatment, or a standard-of-care protocol (with or without riluzole, edaravone, or both).",
author = "H.S. Malhotra and B.P. Singh and N. Kumar and R.K. Garg and R. Kirubakaran and H.C.A. Emsley and S.K. Chhetri and C.A. Mulvaney and G. Villanueva",
note = "This is the version of record of the following protocolMalhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA, Chhetri SK, Mulvaney CA, Villanueva G. Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD013945. DOI: 10.1002/14651858.CD013945. Accessed 12 September 2022 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013945/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving. ",
year = "2022",
month = jun,
day = "24",
doi = "10.1002/14651858.CD013945",
language = "English",
volume = "2022",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol)

AU - Malhotra, H.S.

AU - Singh, B.P.

AU - Kumar, N.

AU - Garg, R.K.

AU - Kirubakaran, R.

AU - Emsley, H.C.A.

AU - Chhetri, S.K.

AU - Mulvaney, C.A.

AU - Villanueva, G.

N1 - This is the version of record of the following protocolMalhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA, Chhetri SK, Mulvaney CA, Villanueva G. Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD013945. DOI: 10.1002/14651858.CD013945. Accessed 12 September 2022 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013945/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

PY - 2022/6/24

Y1 - 2022/6/24

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the efficacy and harms or adverse events of immunomodulatory therapies in people with ALS compared with a placebo, no additional treatment, or a standard-of-care protocol (with or without riluzole, edaravone, or both).

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the efficacy and harms or adverse events of immunomodulatory therapies in people with ALS compared with a placebo, no additional treatment, or a standard-of-care protocol (with or without riluzole, edaravone, or both).

U2 - 10.1002/14651858.CD013945

DO - 10.1002/14651858.CD013945

M3 - Journal article

VL - 2022

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 6

M1 - CD013945

ER -